Abstract
Biomarkers for Alzheimer's disease (AD) should meet several criteria, including simplicity of testing. Inappropriate activation of the complement cascade has been implicated in the pathogenesis of AD. Complement factor H (CFH) is a regulator of the cascade, but studies on plasma CFH levels in AD have provided mixed results. This study compared plasma CFH levels in 317 AD cases with 254 controls using an immunodiffusion assay. The sample had an 80% power to detect a difference of 23 mg/L between cases and controls, but no difference was evident. Plasma CFH may not be a suitable biomarker for AD.
| Original language | English |
|---|---|
| Pages (from-to) | 369-372 |
| Number of pages | 4 |
| Journal | Journal of Alzheimer's disease : JAD |
| Volume | 45 |
| Issue number | 2 |
| Early online date | 07 Jan 2015 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint Dive into the research topics of 'Plasma Complement factor H in Alzheimer's Disease.'. Together they form a unique fingerprint.
Cite this
Williams, M. A., Haughton, D., Stevenson, M., Craig, D., Passmore, A. P., & Silvestri, G. (2015). Plasma Complement factor H in Alzheimer's Disease. Journal of Alzheimer's disease : JAD, 45(2), 369-372. https://doi.org/10.3233/JAD-142742